Avodart and Progesterone HRT Interaction: What Patients and Clinicians Need to Know

Note on this draft: this article is pending qualified clinical review. Several figures in earlier versions of this content (specific trial percentages, a named "Pavlov et al." sleep study, a specific survey percentage for transgender women, and an exact fall-risk fold-increase) could not be verified against a located primary source and have been removed or rewritten as general statements below. Anyone using this page for a prescribing decision should confirm current label language directly.

Direct answer

Dutasteride (brand name Avodart, a 5-alpha reductase inhibitor approved for benign prostatic hyperplasia and used off-label for androgenetic alopecia) has no FDA-labeled contraindication with oral micronized progesterone (brand name Prometrium, used in menopausal hormone therapy and other indications). The two drugs are not known to interact pharmacokinetically in a clinically important way at standard doses. The relevant concern is pharmacodynamic: oral micronized progesterone is independently sedating through its neurosteroid metabolite allopregnanolone, and dutasteride carries fatigue as a reported adverse effect, so the combination may produce additive drowsiness in some patients. This is a monitoring issue, not a contraindication, and the degree of risk depends on progesterone dose, route, patient age, and concurrent CNS-depressant use.

Naming the drugs clearly

• Dutasteride (Avodart): a synthetic 4-azasteroid that inhibits both type-1 and type-2 5-alpha reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT). FDA-approved for benign prostatic hyperplasia. Used off-label for androgenetic alopecia. This is distinct from finasteride, a related but not identical 5-alpha reductase inhibitor with a shorter half-life.
• Progesterone HRT here refers specifically to oral micronized progesterone (e.g., Prometrium), a bioidentical progestogen distinct from synthetic progestins such as medroxyprogesterone acetate. Route matters for this interaction question, and vaginal or transdermal progesterone behave differently (see below).

What is established, what is plausible, and what is not established

This is the core distinction a clinician or pharmacist needs before advising a patient, and it is where generic drug-interaction summaries usually blur together.

Established:

• Oral micronized progesterone produces central nervous system sedation. Its metabolite allopregnanolone is a positive allosteric modulator of GABA-A receptors, a well-characterized neurosteroid mechanism. This is textbook neuroendocrine pharmacology, not a novel or disputed claim.
• Dutasteride and progesterone are each metabolized substantially through hepatic CYP3A4.
• FDA labeling for dutasteride flags potent CYP3A4 inhibitors (for example ritonavir, ketoconazole) as agents that can raise dutasteride blood levels, and it separately notes that fatigue has been reported in clinical trials of dutasteride. The precise wording and current version of the label should be checked directly on DailyMed or the FDA site, since label revisions occur over time.
• FDA labeling for oral micronized progesterone instructs that patients be warned of possible additive CNS-depressant effects when it is combined with other CNS-depressant drugs, and it identifies CYP3A4 inhibitors and inducers as agents that can alter progesterone exposure.
• Neither label lists the other drug as contraindicated.

Plausible but not established with human data available to us:

• That dutasteride's peripheral 5-alpha reductase inhibition could theoretically blunt local conversion of progesterone to allopregnanolone, since 5-alpha reductase participates in that reductive pathway. This is a mechanistically reasonable hypothesis. We did not locate a human pharmacokinetic study that confirms or excludes meaningful allopregnanolone suppression in patients taking both drugs together, so this remains speculative rather than clinically actionable.
• That co-administration meaningfully raises plasma levels of either drug in the absence of a third CYP3A4-inhibiting agent. The competition for CYP3A4 is real in principle, but neither drug is described in its own label as a potent inhibitor or inducer of the other's clearance, so any two-drug effect (without a third interacting agent) is expected to be small.

Not established:

• A quantified rate of clinically significant fatigue or falls specifically from the dutasteride-plus-progesterone combination. We are not aware of a trial that studied this specific pairing as its endpoint. Numbers describing sedation incidence in single-agent trials of dutasteride or of progesterone should not be quoted as if they described the combination.
• A specific percentage of transgender women or older men who use both drugs together. Concurrent use is clinically plausible and reported anecdotally in gender-affirming and geriatric care settings, but a precise prevalence figure would need a verified source before being repeated.

Why this combination comes up in practice

Dutasteride is sometimes used off-label for scalp hair preservation in transgender women undergoing feminizing hormone therapy, where oral progesterone may also be part of the regimen. It is also prescribed for benign prostatic hyperplasia in older men, a population in which progesterone is occasionally used off-label for its sedative or anti-androgenic properties. Both scenarios put two CYP3A4 substrates with different sedation profiles in the same regimen, which is why the question recurs even though it is not a labeled interaction.

The mechanism, plainly

Progesterone taken orally undergoes substantial first-pass hepatic metabolism, producing neurosteroid metabolites, chiefly allopregnanolone, that act on GABA-A receptors in the brain. This is the pharmacological basis for progesterone's well-documented sedative and sleep-promoting effect, and it is the reason oral progesterone is typically dosed at bedtime. Dutasteride does not act on GABA-A receptors. Its relevant adverse-effect profile includes fatigue and sexual side effects tied to DHT suppression, not primary sedation. When both drugs are on board, the concern is additive drowsiness from two different mechanisms landing in the same patient, not a single shared pathway amplifying one effect.

Both drugs also share CYP3A4 as a metabolic route. If a third drug that is a potent CYP3A4 inhibitor (fluconazole, clarithromycin, ritonavir, and grapefruit juice are commonly cited examples in each drug's own labeling) is added, plasma exposure to both dutasteride and progesterone could rise, which would be expected to compound both the sedation risk and any other dose-related effect. This three-drug scenario is the setting where the shared pathway becomes clinically relevant, rather than the two-drug combination alone.

Evidence-status interaction assessment (decision framework for the prescriber or pharmacist)

Use this before combining the two drugs, and again if a third CYP3A4-active drug is added.

Route of administration changes the picture

The sedation concern applies mainly to oral micronized progesterone. Vaginal progesterone (used for endometrial protection or luteal support) achieves high local uterine concentration with much lower systemic exposure, so systemic allopregnanolone generation, and by extension additive sedation with dutasteride, is expected to be substantially lower. Transdermal progesterone creams produce even lower serum progesterone levels and are generally not considered adequate for endometrial protection, but for the same reason carry minimal sedation burden. A patient using vaginal or transdermal progesterone with dutasteride is a different clinical picture than a patient using oral progesterone nightly, and counseling should reflect that.

Practical dose-timing approach

Because oral progesterone's sedative peak occurs roughly 2 to 3 hours after ingestion, a common and physiologically reasonable approach is to take dutasteride in the morning and progesterone at bedtime, separating peak plasma levels of the two drugs by many hours. This is a matter of clinical judgment based on known single-drug pharmacokinetics, not a practice validated by a trial of the combination itself.

Monitoring and when to contact a prescriber

No additional lab panel is required for this combination beyond what each drug already warrants individually (PSA monitoring for dutasteride in BPH, and standard HRT follow-up for progesterone). What does warrant attention:

• Daytime sleepiness that interferes with work, driving, or daily function
• Near-falls or new balance problems, particularly in patients over 65 or with other fall-risk medications on board
• New or worsening mood symptoms, since neurosteroid effects of progesterone can affect mood in susceptible individuals
• Signs of hepatic dysfunction (jaundice, right-upper-quadrant pain, dark urine), since both drugs are hepatically cleared and neither has been well studied in significant hepatic impairment

Patients with Child-Pugh Class B or C liver disease have not been well studied on either drug, and combining them in that setting should involve closer monitoring and a lower threshold for dose reduction of progesterone, since reduced hepatic first-pass metabolism would be expected to raise systemic progesterone and allopregnanolone exposure.

Special populations

Transgender women and gender-diverse patients. Concurrent use of a 5-alpha reductase inhibitor for hair preservation alongside oral progesterone as part of feminizing hormone therapy is a recognized clinical scenario, though we did not locate a verified prevalence figure to cite here. The same sedation-monitoring approach described above applies, with attention to mood given the combined hormonal effects.

Older adults with BPH. Men over 65 taking dutasteride who are also prescribed progesterone (sometimes used off-label for sleep) are a population where CNS-sedating medications in general are associated with increased fall risk, a concern reflected in the American Geriatrics Society Beers Criteria for potentially inappropriate medications in older adults. This is a general geriatric-pharmacology principle rather than a finding specific to the dutasteride-progesterone pairing, and it supports a fall-risk screen rather than a specific numeric risk estimate for this combination.

Patients on a CYP3A4 inhibitor. Adding a potent CYP3A4 inhibitor (fluconazole, clarithromycin, ritonavir, and similar agents named in each drug's own label) to a regimen that already includes both dutasteride and progesterone is the setting where a pharmacokinetic effect is most plausible. A clinician may reasonably consider closer monitoring or a lower progesterone dose in this three-drug scenario, though a specific dose-reduction protocol has not been established in trials and should be individualized.

What the FDA labels actually establish

The dutasteride label addresses CYP3A4 inhibitors as a source of increased dutasteride exposure and recommends monitoring in that setting. The progesterone label addresses additive CNS-depressant effects with other sedating drugs and separately addresses CYP3A4 inhibitors and inducers as factors that can change progesterone exposure. Neither label names the other drug specifically. Because label language is revised periodically, anyone relying on exact wording for a clinical decision should confirm the current label text directly rather than relying on a quotation reproduced secondhand, including in this article. Current labels can be checked on DailyMed (National Library of Medicine) or FDA's own drug label database.

Bottom line

There is no FDA contraindication between dutasteride and oral micronized progesterone, and no evidence of a large pharmacokinetic interaction between the two drugs alone. The practical issue is additive sedation from two different mechanisms, manageable in most patients through dose timing (progesterone at night, dutasteride in the morning) and basic monitoring for daytime sedation and fall risk, with extra caution in older adults, patients with significant liver disease, and anyone also taking a potent CYP3A4 inhibitor. Claims beyond this, including specific percentages for fatigue incidence or fall risk unique to this combination, or a confirmed effect of dutasteride on allopregnanolone production in humans, are not supported by a verified source at this time and should not be presented to patients as established fact.

Common reader questions

Can I take Avodart with progesterone HRT? There is no FDA contraindication. The main practical issue is additive drowsiness, which most patients manage by taking progesterone at bedtime and dutasteride in the morning.

Does dutasteride change progesterone levels in the blood? Not through a well-established mechanism at standard doses. Both drugs share CYP3A4 metabolism, so a third CYP3A4-inhibiting drug could raise levels of both, but dutasteride alone is not described in its label as a meaningful inhibitor or inducer of progesterone clearance.

Does the route of progesterone matter? Yes. Oral progesterone produces more systemic sedative metabolite than vaginal or transdermal progesterone, so the sedation-overlap concern with dutasteride applies mainly to the oral form.

Do I need a dose adjustment? Not as a blanket rule. Dose separation by time of day is a reasonable practical step. A lower progesterone dose may be warranted if a potent CYP3A4 inhibitor is added to the regimen, or in significant liver disease, based on clinical judgment rather than a validated protocol for this specific combination.

When should I call my prescriber? If daytime sleepiness interferes with normal activity, if you have a near-fall or balance problem, if mood symptoms worsen, or if you notice signs of liver trouble such as jaundice or dark urine.

References

• FDA-approved prescribing information for dutasteride (Avodart) and for progesterone (Prometrium), current versions available through DailyMed: https://dailymed.nlm.nih.gov/dailymed/
• American Geriatrics Society Beers Criteria for potentially inappropriate medication use in older adults (general reference for CNS-sedating drug and fall-risk principles in geriatric prescribing)
• General neuroendocrine pharmacology of progesterone and allopregnanolone as a GABA-A receptor modulator (established mechanism, background reference; a specific primary citation for this article was not verified and should be added during medical review)

This article summarizes general pharmacology and labeling information. It does not provide individualized dosing or diagnosis. Anyone changing a medication regimen, especially involving hormone therapy, liver disease, or older-adult polypharmacy, should do so with their prescriber or pharmacist. This draft is pending qualified clinical review and should not be published or relied upon for patient care until that review is complete.